Bayforest Capital Ltd Sells 433 Shares of Zoetis Inc. $ZTS

Bayforest Capital Ltd lowered its position in Zoetis Inc. (NYSE:ZTS) by 14.1% in the second quarter, HoldingsChannel.com reports. The fund owned 2,635 shares of the company’s stock after selling 433 shares during the quarter. Bayforest Capital Ltd’s holdings in Zoetis were worth $411,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Nova Wealth Management Inc. bought a new position in Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at about $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC raised its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.0%

ZTS opened at $142.08 on Thursday. The firm has a 50 day simple moving average of $148.89 and a 200 day simple moving average of $154.03. The company has a market cap of $62.97 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is currently 34.42%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZTS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.